Author:
Chang Lyra,Campbell James,Raji Idris O.,Guduru Shiva K. R.,Kandel Prasanna,Nguyen Michelle,Liu Steven,Tran Kevin,Venugopal Navneet K.,Taylor Bethany C.,Holt Matthew V.,Young Nicolas L.,Samuel Errol L. G.,Jain Prashi,Santini Conrad,Sankaran Banumathi,MacKenzie Kevin R.,Young Damian W.
Abstract
AbstractDespite the established roles of the epigenetic factor UHRF1 in oncogenesis, no UHRF1-targeting therapeutics have been reported to date. In this study, we use fragment-based ligand discovery to identify novel scaffolds for targeting the isolated UHRF1 tandem Tudor domain (TTD), which recognizes the heterochromatin-associated histone mark H3K9me3 and supports intramolecular contacts with other regions of UHRF1. Using both binding-based and function-based screens of a ~ 2300-fragment library in parallel, we identified 2,4-lutidine as a hit for follow-up NMR and X-ray crystallography studies. Unlike previous reported ligands, 2,4-lutidine binds to two binding pockets that are in close proximity on TTD and so has the potential to be evolved into more potent inhibitors using a fragment-linking strategy. Our study provides a useful starting point for developing potent chemical probes against UHRF1.
Funder
National Cancer Institute
Diana Helis Henry and Adrienne Helis Malvin Medical Research Foundations
Publisher
Springer Science and Business Media LLC
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献